Potential target antigens for immunotherapy in human pancreatic cancer

Cancer Letters

Volumn 252, Issue 2, 2007, Pages 290-298

  Schmitz Winnenthal, F H ^a   Galindo Escobedo, L V ^a   Rimoldi, D ^b   Geng, W ^a   Romero, P ^b,c   Koch, M ^a   Weitz, J ^a   Krempien, R ^a   Niethammer, A G ^a   Beckhove, P ^d   Buchler, M W ^a   Z'graggen, K ^a,e  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c National Center of Competence in Research in Molecular Oncology   (Switzerland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e Berner Viszeralchirurgie   (Switzerland)

Author keywords

Cancer testis antigen; HERV K Mel; Pancreatic cancer; Specific immune response; Tumor associated antigens

Indexed keywords

AZACITIDINE; CANCER TESTIS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DRUG MECHANISM; GERM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; AZACITIDINE; BASE SEQUENCE; DNA PRIMERS; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 34249336366     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.003     Document Type: Article

References (32)

1. Lowenfels A.B., and Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn. J. Clin. Oncol. 34 (2004) 238-244
2. Warshaw A.L., and Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326 (1992) 455-465
3. Ferlay J., Bray F., and Sankila R. Cancer Incidence, Mortality and Prevalence in the European Union (1999), IARC Press, Lyon
4. Kawakami Y., Okada T., and Akada M. Development of immunotherapy for pancreatic cancer. Pancreas 28 (2004) 320-325
5. Preuss K.D., Zwick C., Bormann C., Neumann F., and Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol. Rev. 188 (2002) 43-50
6. Abdollahi A., Griggs D.W., Zieher H., Roth A., Lipson K.E., Saffrich R., Grone H.J., Hallahan D.E., Reisfeld R.A., Debus J., Niethammer A.G., and Huber P.E. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin. Cancer Res. 11 (2005) 6270-6279
7. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., and Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94 (1997) 1914-1918
8. Scanlan M.J., Simpson A.J., and Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4 (2004) 1
9. Segal N.H., Blachere N.E., Guevara-Patino J.A., Gallardo H.F., Shiu H.Y., Viale A., Antonescu C.R., Wolchok J.D., and Houghton A.N. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun. 5 (2005) 2
10. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., and Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188 (2002) 22-32
11. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92 (1995) 8078-8082
12. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., and Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22 (1999) 431-440
13. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., and Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80 (1999) 219-230
14. Kubuschok B., Xie X., Jesnowski R., Preuss K.D., Romeike B.F., Neumann F., Regitz E., Pistorius G., Schilling M., Scheunemann P., Izbicki J.R., Lohr J.M., and Pfreundschuh M. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int. J. Cancer 109 (2004) 568-575
15. Bert T., Lubomierski N., Gangsauge S., Munch K., Printz H., Prasnikar N., Robbel C., and Simon B. Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells. Pancreatology 2 (2002) 146-154
16. Schmitz-Winnenthal F.H., Volk C., Z'Graggen K., Galindo L., Nummer D., Ziouta Y., Bucur M., Weitz J., Schirrmacher V., Buchler M.W., and Beckhove P. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 65 (2005) 10079-10087
17. Schiavetti F., Thonnard J., Colau D., Boon T., and Coulie P.G. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 62 (2002) 5510-5516
18. Muster T., Waltenberger A., Grassauer A., Hirschl S., Caucig P., Romirer I., Fodinger D., Seppele H., Schanab O., Magin-Lachmann C., Lower R., Jansen B., Pehamberger H., and Wolff K. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 63 (2003) 8735-8741
19. Rosenberg S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10 (1999) 281-287
20. Boon T., Coulie P.G., and Van den Eynde B. Tumor antigens recognized by T cells. Immunol. Today 18 (1997) 267-268
21. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
22. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E.B., Steinman R.M., Enk A., Kampgen E., and Schuler G. Vaccination with mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190 (1999) 1669-1678
23. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54 (2005) 187-207
24. Gure A.O., Tureci O., Sahin U., Tsang S., Scanlan M.J., Jager E., Knuth A., Pfreundschuh M., Old L.J., and Chen Y.T. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72 (1997) 965-971
25. Gure A.O., Wei I.J., Old L.J., and Chen Y.T. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer 101 (2002) 448-453
26. Ayyoub M., Rimoldi D., Guillaume P., Romero P., Cerottini J.C., Valmori D., and Speiser D. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63 (2003) 5601-5606
27. dos Santos N.R., Torensma R., de Vries T.J., Schreurs M.W., de Bruijn D.R., Kater-Baats E., Ruiter D.J., Adema G.J., van Muijen G.N., and van Kessel A.G. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 60 (2000) 1654-1662
28. Lower R., Lower J., and Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc. Natl. Acad. Sci. USA 93 (1996) 5177-5184
29. Goedert J., Sauter M., Jacobson L., Vessella R., Hilgartner M., Leitman S., Fraser M., and Mueller-Lantzsch N. High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. Cancer Epidemiol. Biomarkers Prev. 8 (1999) 293-296
30. Sauter M., Schommer S., Kremmer E., Remberger K., Dolken G., Lemm I., Buck M., Best B., Neumann-Haefelin D., and Mueller-Lantzsch N.G. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J. Virol. 69 (1995) 414-421
31. Stauffer Y., Theiler G., Sperisen P., Lebedev Y., and Jongeneel V. Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues. Cancer Immun. 4 (2004) 2
32. Gotzinger N., Sauter M., Roemer K., and Mueller-Lantzsch N. Regulation of human endogenous retrovirus-K Gag expression in teratocarcinoma cell lines and human tumours. J. Gen. Virol. 77 Pt 12 (1996) 2983-2990